文献速递生殖医学

生育力保护:一种利用间充质干细胞外泌体预处理预防化疗所致卵巢损伤的小鼠模型新方法

Fertility protection: a novel approach using pretreatment with mesenchymal stem cell exosomes to prevent chemotherapy-induced ovarian damage in a mouse model.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-18

该研究将60只小鼠分为对照组、化疗组和生育力保护组(每组20只),生育力保护组在化疗前卵巢内注射间充质干细胞外泌体,化疗组和对照组注射生理盐水。结果显示外泌体预处理可维持动情周期、血清抗苗勒管激素水平、卵泡发生、类固醇生成急性调节蛋白基因表达及生育力,并可能通过上调ABCB1b和ABCC10等ATP结合盒转运蛋白发挥作用。

要点

  • 化疗前卵巢内注射间充质干细胞外泌体可维持小鼠动情周期(4-5天周期性)。
  • 生育力保护组卵泡发生数及生育率高于化疗组,差异有统计学意义。
  • 外泌体预处理可能通过上调ABCB1b和ABCC10等ATP结合盒转运蛋白保护卵巢功能。

核心结论

  • 间充质干细胞外泌体是一种有前景且简单的生育力保护方法,可能适用于接受性腺毒性化疗的育龄患者。

研究设计与样本

  • 研究为小鼠模型实验,共60只小鼠分为3组(每组20只):对照组、化疗组和生育力保护组。
  • 仅生育力保护组小鼠接受外泌体,对照组和化疗组接受生理盐水;随后化疗组和生育力保护组接受化疗诱导卵巢损伤。

主要发现

  • 生育力保护组小鼠维持动情周期(4-5天周期性)及血清抗苗勒管激素水平(66.06±26.40 ng/mL,与健康对照组无显著差异)。
  • 卵泡发生数:化疗组32.2±11.3 vs 生育力保护组46.4±14.1(P<.05)。
  • 类固醇生成急性调节蛋白基因表达:化疗组0.44±0.11倍 vs 生育力保护组0.88±0.31倍(P<.05)。
  • 生育率:化疗组8只中2只 vs 生育力保护组8只中5只。
  • ABCB1b表达:化疗组10.17±17.75倍 vs 生育力保护组44.14±33.25倍(P<.05);ABCC10表达:化疗组3.25±0.59倍 vs 生育力保护组5.36±1.86倍(P<.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary ovarian insufficiency refers to the loss of ovarian function before the age of 40 years and leads to amenorrhea and infertility. Primary ovarian insufficiency has diverse causes, but a common cause is exposure to gonadotoxic chemotherapy used in cancer treatment. Because of the risk for developing primary ovarian insufficiency, patients who want to preserve their fertility may consider various procedures for fertility preservation. However, current fertility preservation options are highly invasive, carry substantial risks, and have uncertain success rates. Recent studies from our group and others reported that mesenchymal stem cells and mesenchymal stem cell-derived exosomes can restore ovarian function in preclinical models of primary ovarian insufficiency by restoring damaged cells and inhibiting apoptosis. Although the restorative effect of mesenchymal stem cell-derived exosomes has been well reported in previous studies, the potential of mesenchymal stem cell-derived exosomes in preventing ovarian damage has not been fully elucidated. OBJECTIVE: This study hypothesized that the antiapoptotic potential of mesenchymal stem cell-derived exosomes may protect ovarian tissue from chemotherapy-induced damage. STUDY DESIGN: In this study, we delivered mesenchymal stem cell-derived exosomes directly into the ovaries of mice before administration of chemotherapy. A total of 60 mice were divided into 3 groups (20 per group), which were labeled the control, chemotherapy, and fertility protection groups. Only the fertility protection group mice received exosomes, whereas the control and chemotherapy group mice received saline. After exosome injection, the chemotherapy and fertility protection groups of mice were subjected to chemotherapy to induce ovarian damage. After chemotherapy, we evaluated the protective effects of exosome treatment on ovarian function, such as estrous cyclicity, serum hormone levels, and the fertility rate, by comparing these outcomes between the chemotherapy and fertility protection groups. These outcomes were also compared with those of the control group for comparison with outcomes under healthy conditions. RESULTS: After intraovarian injection of exosomes before chemotherapy, the mice were able to maintain their estrous cycle (4- to 5-day cyclicity), serum anti-müllerian hormone level (66.06±26.40 ng/mL, not significantly different from that of the healthy controls), folliculogenesis (32.2±11.3 in the chemotherapy group vs 46.4±14.1 in the fertility protection group; P<.05), expression of the steroidogenic acute regulatory protein gene (a the steroidogenesis marker) (0.44±0.11-fold expression in the chemotherapy group and 0.88±0.31-fold expression in the fertility protection group; P<.05), and fertility (2 of 8 in the chemotherapy group and 5 of 8 in the fertility protection group), thereby showing prevention of chemotherapy-induced damage. We found that exosome treatment before chemotherapy can preserve ovarian function and protect fertility through the overexpression of ATP synthase-binding cassette transporters, such as ABCB1b (10.17±17.75-fold expression in the chemotherapy group and 44.14±33.25-fold expression in the fertility protection group; P<.05) and ABCC10 (3.25±0.59-fold expression in the chemotherapy group and 5.36±1.86-fold expression in the fertility protection group; P<.05). CONCLUSION: In this study, we present a novel fertility protection method using mesenchymal stem cell-derived exosomes. We concluded that mesenchymal stem cell-derived exosomes are a promising and simple treatment option for fertility protection in reproductive-aged patients who are receiving gonadotoxic chemotherapy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Park HS, Seok J, Cetin E, et al. Fertility protection: a novel approach using pretreatment with mesenchymal stem cell exosomes to prevent chemotherapy-induced ovarian damage in a mouse model. Am J Obstet Gynecol. 2024. PMID: 38378099. doi:10.1016/j.ajog.2024.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。